

1 Invited Review for Reproduction, special edition on ‘Women Leaders in Reproductive Research.

2

3

4 **My WOMBan’s Life: Understanding Human Endometrial Function**

5 Lois A. Salamonsen

6 Centre for Reproductive Health

7 Hudson Institute of Medical Research

8 Clayton, Victoria 3168

9 Australia

10

11

12 *Corresponding Author:*

13 Professor Lois Salamonsen

14 Centre for Reproductive Health

15 Hudson Institute of Medical Research

16 27-31 Wright St, Clayton

17 Victoria 3168, Australia

18 Email: [lois.salamonsen@hudson.org.au](mailto:lois.salamonsen@hudson.org.au)

19

20 Short title: Understanding human endometrial function

21

22

**23 Abstract**

24 The focus of my life in science has been to improve reproductive health for women, with an  
25 emphasis on the endometrium, the most dynamic tissue in the human body: its remarkable cyclical  
26 remodelling is essential for establishment of pregnancy. The most notable events in a woman's  
27 endometrial cycle are menstruation and endometrial repair, regeneration of the endometrium during  
28 the proliferative phase, attainment of receptivity by the mid-secretory phase of the cycle and the  
29 embryo-maternal interactions that initiate peri-implantation events within the microenvironment of  
30 the uterine cavity. I have contributed to understanding the molecular and cellular changes  
31 underpinning these events, and how disturbance of them leads to menstrual disorders, infertility and  
32 endometrial diseases including abnormal uterine bleeding, endometriosis and endometrial cancer.  
33 My team have contributed to changes in clinical IVF practice, to a new diagnostic for endometrial  
34 receptivity in infertile women, and to enhancing endometrial repair. I have shared my world with  
35 many amazing younger scientists: it has indeed been a privileged journey.

36

## 37 **Introduction**

38 My first introduction to the topic of reproductive processes was as a young research assistant  
39 working with Professor Henry Burger and the late Dr James R. Goding Sr, at the then Medical  
40 Research Centre at Prince Henry's Hospital in Melbourne, Australia. This was at the start of the  
41 1970's when the technique of radioimmunoassay (RIA), first developed by Sol Berson and Rosalyn  
42 Yalow (Berson and Yalow 1968), was being applied to reproductive hormones. With Henry Burger,  
43 I developed the first RIA for ovine FSH which enabled recognition of its pulsatile release  
44 (Salamonsen, et al. 1973). I became fascinated by the physiology of reproduction, and later, after a  
45 substantial period out of the workforce for motherhood (as common in those days), I undertook a  
46 PhD under the supervision of Professor Jock Findlay at Prince Henry's Institute of Medical Research.  
47 He had an interest in embryo implantation and I took up a project to examine molecular mechanisms  
48 underpinning implantation in sheep. This work, which focussed on identifying endometrial protein  
49 changes in ovine tissue and uterine fluid under different steroidal stimulation and during very early  
50 pregnancy (Salamonsen LA 1986, Salamonsen, et al. 1985), stimulated and underpinned my  
51 subsequent long term interest in endometrial function and strong focus on improving female  
52 reproductive health.

53 Over the next 30 years my interests evolved, in part by identifying clinical needs for basic science  
54 that would underpin and modify evidence-based clinical practice to improve women's reproductive  
55 wellbeing and also in response to availability of funding. Another strong driver was the opportunity  
56 to perform more complex molecular and cellular analyses as new technologies became available.

57 My specific interests have focussed around the extensive remodelling that occurs within the  
58 endometrium, particularly the mechanisms underpinning menstruation and abnormal uterine bleeding  
59 and development of endometrial receptivity for successful embryo implantation, in addition to  
60 unravelling the microenvironment of implantation within the uterine cavity. Given that disturbances

61 of endometrial remodelling severely affect women's health, my team has also contributed to our  
62 understanding of infertility, endometriosis and endometrial cancer. Further, we have identified a  
63 number of targets for new women-centred non-steroidal contraceptives: regrettably, funding bodies  
64 and pharmaceutical companies in the western world are not yet accepting of post-coital contraception.  
65 Some of our discoveries have laid the groundwork for changes to clinical practice while new models  
66 we have developed for the study of 'human' problems which cannot be studied in vivo, have  
67 subsequently been adapted by others and enabled new discoveries. The remainder of this review  
68 focuses on some of the major contributions from my laboratory, placing them in the framework of  
69 current knowledge, and how they have progressed our understanding of endometrial function in  
70 women. A brief personal profile along with a list of some of my published research is presented in  
71 Box 1.

## 72 **Mechanisms of menstruation and endometrial repair**

73 Menstruation is the process whereby most of the functionalis layer of the endometrium is shed,  
74 accompanied by bleeding from the fragmented blood vessels, at the end of each non-conception  
75 menstrual cycle (reviewed: (Salamonsen 2018)). It occurs in only a limited number of species  
76 including women, old world primates, some bats and the spiny mouse (Bellofiore, et al. 2018) and is  
77 a response to the rapid fall in levels of progesterone and estradiol-17 $\beta$  that accompany the demise of  
78 the corpus luteum. Current knowledge indicates that menstruation is limited to these species, since  
79 they are the only ones in which the endometrial stroma undergoes the process of differentiation  
80 known as decidualization, during the secretory phase, even in the absence of an embryo. Since this is  
81 irreversible, the endometrium must be shed and replaced to provide an opportunity for implantation  
82 in the next cycle. Menstrual shedding, as observed by scanning electron microscopy (Ferenczy and  
83 Richart 1973, Ludwig and Spornitz 1991), occurs at focal points, with rapid re-epithelialisation of the  
84 shed surface occurring even as shedding is initiated at adjacent sites. The first day of bleeding is by  
85 definition, day 1 of the next menstrual cycle.

## 86 Menstrual breakdown

87 The withdrawal of steroidal control of the endometrium initiates a sequence of events leading to  
88 menstrual breakdown (Figure 1) and these represent a highly controlled inflammatory process (Finn  
89 1986). Progesterone is an inhibitor of inflammation, as evidenced in mice lacking the progesterone  
90 receptor (PR) in which the uterus is highly inflamed (Lydon, et al. 1995). The initial response to  
91 falling progesterone in a non-conception cycle (when the corpus luteum is not rescued by hCG),  
92 occurs within the decidualized stromal cells, which express the PR and respond to progesterone  
93 withdrawal by intracellular processes known for their role in inflammation. These include decreased  
94 cytoplasmic I-kappaB and a progressive increase in NF-kappaB accumulation in the nucleus. In  
95 parallel a host of pro-inflammatory mediators, including chemokines and cytokines, are released: this  
96 can be abrogated by an inhibitor of NF-kappaB (Evans, et al. 2011) (Evans and Salamonsen 2012).

97 Leukocytes are present in the endometrium in only small numbers during the proliferative phase of  
98 the cycle, but uterine natural killer cells (uNK, increase in the mid-secretory phase with their  
99 proliferation and differentiation occurring in response to IL15 induced by progesterone acting on the  
100 stromal cells (Kitaya et al, PMID:15713701) ; these are associated with endometrial receptivity.  
101 However, during the late secretory phase, in response to progesterone withdrawal and the  
102 chemokines and cytokines released into the tissue from the decidualized cells, there is a massive  
103 influx of inflammatory cells including macrophages (Figure 1A), but predominantly granulocytes  
104 (neutrophils, mast cells, eosinophils, basophils), which become activated locally (Figure 1B). These  
105 release factors such as degradative enzymes and cytokines stored in their intracellular granules, but  
106 also chemo-attractants for uNK and monocytes/macrophages (Salamonsen and Woolley 1999).

107 These inflammatory cells comprise up to 50% of the total cells in peri-menstrual endometrium and  
108 set up a cascade of events that lead to tissue destruction. Since uNK cells predominate prior to the  
109 menstrual cascade, their major role is most likely during pregnancy when they are important  
110 components of pregnancy decidua that orchestrate vascular adaption and trophoblast invasion(Hanna,

111 et al. 2006) (Xiong, et al. 2013). However, there is evidence that within the late secretory phase of  
112 the cycle, once decidualization has commenced, the uNK cells selectively target and clear senescent  
113 decidual cells through granule exocytosis (Brighton, et al. 2017) .

#### 114 *Extracellular matrix breakdown*

115 Matrix metalloproteinases (MMP) are the family of enzymes primarily responsible for breakdown  
116 of extracellular matrix: different enzymes have specific substrate specificities. The first indication  
117 of the in vivo association of MMPs with menstruation, using Northern blot on endometrial samples  
118 taken from across the cycle, showed clearly that MMP1 and MMP3 mRNA were highly expressed  
119 only immediately before and during menstruation (Hampton and Salamonsen 1994) and,  
120 subsequently, we and others identified a range of MMP mRNA and protein capable of fully  
121 breaking down the endometrial ECM in peri-menstrual endometrium (Rodgers, et al. 1994)  
122 (Jeziorska, et al. 1996, Marbaix, et al. 1996). MMP expression in human endometrium is regulated  
123 both by withdrawal of progesterone (Marbaix, et al. 1992, Zhang, et al. 2000) and also by locally  
124 produced cytokines including IL1 $\beta$  and TNF $\alpha$  (Rawdanowicz, et al. 1994). MMPs are released as  
125 latent forms requiring extracellular cleavage for activity: in vivo they are balanced by natural  
126 inhibitors (TIMPs) that bind the active forms with a 1:1 stoichiometry. This provides stability of  
127 tissues as it is only when active MMPs are present in excess of the TIMPs that ECM degradation  
128 can occur. MMP activators include other MMPs (providing a cascade of activity), enzymes from  
129 leukocytes including mast cell chymase and tryptase and cytokines (Salamonsen and Lathbury 2000)  
130 (Figure 1B, (Zhang, et al. 1998). Using in situ zymography, focal sites of MMP activity were  
131 demonstrated in menstrual endometrium, supporting that MMPs that are likely primarily  
132 responsible for tissue degradation at menstruation while the focal activation highlights the  
133 mechanism underpinning the piecemeal nature of menstrual tissue breakdown (Figure 1C; (Zhang  
134 and Salamonsen 2002). New mechanisms by which MMPs are so tightly regulated are emerging,

135 and include inhibition of endocytic clearance by the low density lipoprotein receptor-related  
136 protein-1 (LRP-1) by ectodomain shedding (Gaide Chevronnay, et al. 2012).

### 137 *Mouse models of menstruation*

138 Since it is possible to undertake only ‘snapshots in time’ of endometrial tissue in women, a good  
139 animal model for menstruation is needed. Colin Finn (Finn and Pope 1984) first developed a mouse  
140 model for menstruation, providing proof that both progesterone withdrawal and artificial  
141 decidualization (which occurs only in response to an embryo in mice), were essential for menstrual  
142 breakdown. This was refined by us in the early 2000’s (Brasted, et al. 2003) and has since been  
143 modified by others (Armstrong, et al. 2017, Cousins, et al. 2014, Menning, et al. 2012, Xu, et al.  
144 2013) providing insights into molecular and cellular mechanisms of breakdown and repair detailed  
145 below.

146 Recently, the spiny mouse, a native to the deserts of Africa and the Middle East, has been shown to  
147 undergo menstruation very similar to that in women. It demonstrates similar variation in degree of  
148 menstrual bleeding with some females having noticeable heavy periods along with inflammation,  
149 breakdown and repair processes as in women. This menstruation occurs for approximately 72 hours  
150 every nine days (Bellofiore, et al. 2018), making this a very useful laboratory model for study of the  
151 human condition.

152

### 153 Endometrial repair

154 Redevelopment of Finn’s mouse model of menstruation, particularly enabled molecular evaluation  
155 of endometrial repair, which is essential to stop menstrual bleeding and which, uniquely, is scar free.  
156 As previously shown in menstruating women by scanning electron microscopy, endometrial repair  
157 in the mouse model occurs simultaneously at focal points, adjacent to those which are still  
158 undergoing breakdown. Importantly, initial repair (re-epithelialisation) can take place in the

159 complete absence of estrogen (Kaitu'u-Lino, et al. 2007a) but is hampered by androgen (Cousins, et  
160 al. 2016). Furthermore, activins stimulate repair (Kaitu'u-Lino, et al. 2009) and neutrophil influx is  
161 essential (Kaitu'u-Lino, et al. 2007b). In a similar mouse model, physiological endometrial hypoxia  
162 and decreased HIF-1 $\alpha$ , occur during bleeding while maintenance of the mice under hyperoxia  
163 during menses both decreases HIF-1 $\alpha$  induction and delays repair (Maybin, et al. 2018). In a unique  
164 approach, Jemma Evans proposed that as repair occurs in the presence of menstrual effluent, this  
165 fluid would contain repair factors. Application of menstrual fluid to in vitro endometrial wound  
166 models dramatically enhanced re-epithelialization. Differential proteomic analysis of menstrual  
167 serum versus blood serum (collected at the same time) identified both unique and upregulated  
168 proteins in menstrual serum. These included proteases, anti-proteases, antimicrobials and factors  
169 protective against stress, along with others that could be predicted to facilitate post-menstrual repair.  
170 Indeed, a number of the identified proteins were functionally active in promoting endometrial repair  
171 in vitro (Evans, et al. 2018).

### 172 Abnormal uterine bleeding

173 Abnormal uterine bleeding (AUB) is a major issue for women and their families. In women using  
174 long-acting progestin only contraceptives (such as the implantable Implanon and the impregnated  
175 IUD, Mirena), AUB primarily takes the form of irregular spotting. However, such irregularity is the  
176 major reason for women discontinuing these very effective contraceptives. With support from the  
177 World Health Organisation, we and others, investigated the mechanisms underpinning this bleeding.  
178 One cause identified was inadequate control of MMP actions by different mechanisms: local  
179 disturbance of TIMPs and excessive leukocyte activation (Vincent, et al. 1999, Vincent, et al. 2000).  
180 Regrettably, clinical trials of treatments for frequent and/or controlled bleeding in women using  
181 Implanon, based on this knowledge (Weisberg, et al. 2006, 2009), showed that while mifepristone  
182 combined with ethinyl estradiol or doxycycline (which inhibits MMP action) was effective in  
183 stopping a specific bleeding episode, it showed no improvement in subsequent bleeding episodes.



184 In users of hormone replacement therapy, irregular bleeding is also associated with a distinct pattern  
185 of MMP and TIMP production, but this differs from that seen in normal menstrual bleeding and from  
186 that seen in contraceptive-related breakthrough bleeding. Again, evidence supports that the balance  
187 between MMP and TIMP in the endometrium contributes to vascular breakdown with HT but by a  
188 different mechanism than that seen in normal menstruation or in breakthrough bleeding (Hickey, et al.  
189 2006).

190 There is still a clear need for treatments for abnormal uterine bleeding. It is to be hoped that others  
191 will continue this quest using new knowledge and models,.

192

### 193 **Endometrial receptivity for implantation**

194 Cyclical remodelling is the major feature of the endometrium in most, if not all, species but is most  
195 extreme in women. It is driven primarily by the cyclical production of the ovarian hormones  
196 estradiol-17 $\beta$  and progesterone and serves to prepare the endometrium for implantation of a  
197 blastocyst in a conception cycle. However, the endometrium is 'receptive' only for about 4 days  
198 (Navot, et al. 1991, Wilcox, et al. 1999) in the mid-secretory phase of each menstrual cycle. At this  
199 time, all the cell types in the endometrium, particularly the epithelial cells and the stromal fibroblasts  
200 have differentiated in response to the rising progesterone following ovulation. A receptive  
201 endometrium is essential for implantation when a hatched blastocyst attaches to and penetrates the  
202 luminal epithelium to begin its invasion through the decidualizing stroma (Figure 2). It is now clear  
203 that at least some of the unexplained infertility in women is a result of failure to attain receptive  
204 endometrium. We have sought to identify the critical signalling molecules that lead to receptivity and  
205 implantation.

206 Our first discovery studies for endometrial factors involved in implantation utilized the then new  
207 technique of RNA differential display, comparing expression levels in implantation versus inter-

208 implantation sites in mice on day 4.5 of pregnancy, just when the blastocyst was first in contact with  
209 the endometrium. Five of the transcripts identified encoded proteins which were further investigated:  
210 (Nie, et al. 2000b), MNSF $\beta$  (Nie, et al. 2000a), the High temperature resistant protein A3 (HtrA3; its  
211 first identification) (Nie, et al. 2003a), pro-protein convertase 5/6 (Nie, et al. 2003b), splicing factor  
212 SC35 (Nie, et al. 2002) and Calbindin d9k (Nie, et al. 2000b). Knockdown or inhibition of four of  
213 these demonstrated that they were each essential for implantation in mice: all but calbindin d9k were  
214 similarly expressed in receptive human endometrium: due to evolution, in women calbindin 28k  
215 most likely performs the same role (Luu, et al. 2004). PC6 and HtrA3 are both proteases and  
216 identification of their specific substrates has provided insight into pathways essential for  
217 implantation, potential targets for contraception, and a potential use in identifying receptive  
218 endometrium (see below).

219 A key role for cytokines in implantation was first demonstrated in leukaemia inhibitory factor (LIF)  
220 null mice which exhibited failure of implantation (Stewart, et al. 1992). Interestingly, extension of  
221 this work to human implantation, showed that while LIF contributes to receptivity in women, it is not  
222 essential (Paiva, et al. 2009). Indeed treatment of infertile women with LIF failed to improve  
223 implantation rates (Brinsden, et al. 2009). We further established that another related cytokine,  
224 interleukin (IL)11, whose receptor (R), as for LIFR, is present on endometrial epithelium, and also  
225 plays a role in implantation, regulating the adhesiveness of primary endometrial epithelial cells,  
226 likely though upregulation of both flotillin-1 and annexin A2 (Yap, et al. 2011), which are  
227 themselves proposed to be essential for implantation. Furthermore, IL11, IL6 fibroblast growth  
228 factor (FGF)2, CXCL10, vascular endothelial growth factor (VEGF) and granulocyte-macrophage  
229 growth factor (GM-CSF) are all regulated in endometrial epithelium by blastocyst-derived human  
230 chorionic growth factor (hCG) (Licht, et al. 2001, Paiva, et al. 2011), demonstrating the importance  
231 of the blastocyst signalling in establishment of pregnancy. IL11 is also one of a number of cytokines,  
232 including activin A, that drive decidualization via different pathways (Menkhorst, et al. 2010).

233 The luminal epithelium is the first point of contact of the blastocyst with the endometrium. At the  
234 time of implantation this undergoes a 'plasma membrane transformation' (Murphy 2004)  
235 accompanied by loss of junctional integrity and adhesive molecule changes at the apical surface  
236 (Aplin and Ruane 2017). In women, PC6 acting via its proteolytic activity, post-translationally  
237 regulates anti-adhesion molecules (including dystroglycan, and integrins (Heng, et al. 2015, Paule,  
238 et al. 2012) and reorganizes the plasma membrane altering the apical architecture to provide a  
239 receptive surface (Heng, et al. 2011). Further, actin linkage to the apical plasma membrane is  
240 regulated by the ERM proteins, ezrin, moesin and radixin (Martin, et al. 2000): PC6 cleaves the  
241 ERM-binding phosphoprotein EBP50, which tethers ezrin to the membrane: knockdown of PC6,  
242 stabilizes membrane localization of ERMs, thus preventing the rearrangement of the actin  
243 microfilament web essential for receptivity (Heng, et al. 2011).

244 Changes in epithelial apical-basal polarity, first proposed by Denker (Denker 1993), are needed for  
245 progression of implantation following adhesion, enabling the trophoctodermal cells to move between  
246 the epithelial cells and penetrate the stromal compartment. In the endometrial epithelial cell line  
247 ECC1 (the closest representative of luminal epithelium), combined estrogen/progesterone treatment  
248 to mimic the mid-secretory phase of the cycle downregulated polarity (measured by reduced  
249 transepithelial resistance). Importantly, defined polarity markers (Stardust, Crumbs and Scribble)  
250 were downregulated in endometrial biopsies during the progression from the proliferative to the  
251 secretory phase while knockdown of Scribble in the ECC1 cells, enhanced trophoctodermal adhesion  
252 (Whitby, et al. 2018). Interestingly, this loss of polarity is further driven by hCG, a product of the  
253 pre-implantation blastocyst, via its receptor (the LHCGR) on the epithelial cells (Evans and  
254 Salamonsen 2013).

255

256 **Uterine microenvironment of implantation**

257 Uterine fluid provides the microenvironment for blastocyst hatching and final development, and for  
258 the first stages of implantation (Salamonsen, et al. 2016) (Figure 2). It contains highly selected serum  
259 proteins (albumin and immunoglobulins are particularly abundant) (Hannan, et al. 2009), along with  
260 contributions from Fallopian tube fluid, leukocyte activation, semen and the blastocyst (in a  
261 conception cycle). Salts, sugars, amino acids, lipids, hormones, carbohydrates, RNA forms and other  
262 nutrients are also present. Importantly uterine fluid is enriched in soluble proteins secreted from the  
263 endometrial luminal epithelium and glands and in secreted extracellular vesicles (EVs). Analysis of  
264 uterine fluid may provide a useful window to detect whether or not receptivity has been achieved  
265 (Salamonsen, et al. 2013) and to detect diseases of the reproductive tract (Lopata, et al. 2003).

266 Uterine gland secretions are unequivocally required for establishment of pregnancy as shown by  
267 landmark studies in sheep (Gray, et al. 2001) and mice (Filant and Spencer 2013), in which the  
268 development of uterine glands was totally inhibited (uterine gland knockout). The ewes showed  
269 retarded conceptus development and no implantation while in the female mice there was no  
270 decidualization and no implantation.

271 In women, the endometrium is rich in glands, with approximately 15 gland openings for every  
272 millimetre of uterine surface in the secretory phase (Burton, et al. 2002), thus secretions into the  
273 uterine cavity are abundant, particularly during the mid-secretory phase when the glands are fully  
274 differentiated for secretion. Analysis of human uterine fluid has utilized either uterine aspirate or  
275 lavage: these provide somewhat different results, probably since lavage washes the uterine surface,  
276 removing loosely bound molecules or those trapped locally by the glycocalyx (Hannan, et al.  
277 2012). Multiplex cytokine/chemokine analyses have measured many of these important mediators  
278 in uterine fluid and shown that their levels differ between fertile and infertile women and in the  
279 proliferative compared with the secretory phase (Boomsma, et al. 2009, Fitzgerald, et al. 2016,  
280 Hannan, et al. 2011). In some cases, functional studies indicated their roles: for example, VEGF  
281 promotes human endometrial epithelial cell adhesive capacity and mouse blastocyst outgrowth in

282 vitro and along with placental growth factor (PLGF) enhances embryo development and  
283 implantation in mice (Binder, et al. 2014, Binder, et al. 2016, Hannan, et al. 2011).

284 With the recent advent of sophisticated proteomics, uterine fluid has been examined in an unbiased  
285 manner: many proteins already known as important for receptivity have been confirmed, and other  
286 novel proteins also identified in secretory phase fluid (Casado-Vela, et al. 2009, Hannan, et al. 2010,  
287 Scotchie, et al. 2009). Validation is typically absent while bioinformatics and functional assays could  
288 indicate possible actions. Interestingly, proteomic analyses of proliferative phase proteins and  
289 glycoproteins have indicated that in some idiopathic infertile women, the endometrium is developing  
290 in an environment of increased inflammation, thus inadequately priming the endometrium for  
291 development of receptivity (Fitzgerald, et al. 2018, Fitzgerald, et al. 2016) and personal  
292 communication). Some of the proteins altered in the proliferative phase were further validated: for  
293 example extracellular matrix protein 1 (ECM1) is secreted by both primary endometrial epithelial and  
294 stromal cells and is not regulated by estrogen. It is a biotransporter, binding many partners among  
295 which are a number of extracellular matrix proteins; hence ECM1 may influence endometrial  
296 regeneration and development.

297 To determine the hormonal regulation of uterine fluid proteins, we analysed the soluble secreted  
298 proteomes of ECC1 cells, appropriately treated to represent the proliferative (estrogen alone) and  
299 secretory phases of the cycle (estrogen plus progesterone following estrogen priming), and also in  
300 the presence of the embryo-derived hCG. There were substantial unique protein changes between  
301 these. Of 1059 proteins identified, 123 were significantly altered by progesterone (mostly  
302 downregulated) (Figure 3) and 43 proteins altered by hCG. The identified proteins were associated  
303 with cellular adhesion, ECM organisation, developmental growth, growth factor regulation and cell  
304 signalling. Many of the changes were validated in primary endometrial epithelial cells (Greening, et  
305 al. 2016b). Several proteins were common to those in the secretory phase described by (Scotchie, et  
306 al. 2009) and 15 had been identified in our previous analyses (Hannan, et al. 2010). Interestingly, the

307 enzymatic protein superoxide dismutase (SOD1), which is an important antioxidant defense, was  
308 elevated in response to hCG, and hence has a potentially important role in endometrial-embryo  
309 communication.

### 310 **Extracellular vesicles: part of the cellular secretome**

311 The term ‘secretome of a cell’ has recently been redefined to include the totality of organic and  
312 inorganic elements secreted from cells either as soluble forms or within EVs produced via  
313 endosomal-exocytosis (Wikipedia). EVs are nano-sized particles, released from all cells. They  
314 provide communication with other cells, even at some distance, by delivery of their complex cargo  
315 via cell-specific docking sites. This alters the phenotype of the recipient cells, contributing to both  
316 physiological and pathological processes. Importantly, the molecular ‘cargo’ (that includes RNA,  
317 miRNA, DNA, lipids and proteins) is protected from extracellular degradation. EVs can be divided  
318 by size and specific marker proteins into apoptotic bodies, microvesicles and exosomes and  
319 separated by differential ultracentrifugation. Apoptotic bodies are removed at 10,000g and the others  
320 pellet at 100,000g: it is the latter fraction that is generally used in functional studies. Further  
321 separation can be achieved by density gradient centrifugation (Nguyen, et al. 2016) to provide the  
322 highly purified fractions essential for proteomic analyses.

323 We were the first to identify EVs in human uterine fluid and that these contained a unique cohort of  
324 proteins and miRNA (Greening, et al. 2016a, Ng, et al. 2013) respectively, differing from those of  
325 the parent endometrial epithelial cells. The contents of endometrial epithelial exosomes, prepared  
326 from the secretions of ECC1 cells, are programmed by ovarian steroid hormones (as are the soluble  
327 secreted products), with the protein profiles differing from those of the soluble secretome and the  
328 cellular proteome of the same cells. Analyses of the exosomal proteomes defined a total of 1043  
329 exosomal proteins, of which 254 were regulated by estrogen (E) alone and 126 by combined estrogen  
330 plus progesterone (EP). More exosomal proteins were downregulated, than upregulated by EP vs E,

331 and these were in the categories of basement membrane, cell adhesion, and extracellular  
332 matrix/cytoskeletal proteins (Greening, et al. 2016a). Importantly these endometrial epithelial  
333 exosomes have a unique proteome compared with exosomal proteins from other tissues and cancers  
334 ([www.exocarta.com](http://www.exocarta.com)) with ~10% of the proteins not detected in exosomes from other sources.  
335 Functionally, endometrial exosomes are taken up by trophoblast (HTR8) cells, by the  
336 trophoctodermal stem cell line TSC (Evans J, Greening DW, Salamonsen LA, unpublished  
337 observations), by mouse blastocysts (Catt S, Nguyen H, Salamonsen LA, unpublished observations)  
338 and also by endometrial epithelial cells themselves (Salamonsen LA, Greening DW, Evans J, Gurung  
339 S, Roslee AM unpublished). In the HTR8 cells, exosomal uptake enhanced trophoblast adhesive  
340 capacity (as measured by xCelligence) via the Fak-kinase pathway (Greening, et al. 2016a), while in  
341 mouse blastocysts, exosomal uptake enhanced outgrowth. Most physiologically relevant is that in a  
342 human implantation model that quantitates trophoctodermal spheroid attachment to an endometrial  
343 epithelial cell monolayer (Evans J, Greening DW, Walker KJ, Bilandzic M, Kinnear S, Hutchinson J,  
344 Salamonsen LA, submitted), inclusion of endometrial exosomes enhanced both spheroid adhesion  
345 and attachment (Evans J, Salamonsen LA, unpublished observations).

#### 346 **Clinical applications**

347 Our emphasis has been on studying human endometrium with a view to clinically relevant outcomes;  
348 while many studies have ‘placed another piece in the jigsaw’ of knowledge that will subsequently  
349 lead to translation, some have/will have direct clinical implications.

#### 350 Change in IVF practice to ‘Freeze-all’

351 Regrettably, infertility clinics have had an embryocentric view since IVF was introduced, with the  
352 main aim being to produce a good blastocyst for transfer. However the endometrium, which is  
353 equally as important, has remained the ‘black box of early pregnancy loss’ and indeed implantation  
354 (Macklon, et al. 2002). In 2014, we presented a strong case for frozen embryo transfer, based on both

355 scientific and clinical evidence (Evans, et al. 2014) which underpinned what has been a slow change  
356 from previous international practice. In Australia, such ‘freeze-all cycles, increased from 5% of fresh  
357 cycles in 2011 to almost one in five cycles in 2015, with numbers still rising but statistics not yet  
358 available (National Perinatal Epidemiology and Statistics Unit, University of NSW’s Centre for Big  
359 Data Research in Health and School of Women’s and Children’s Health maintained on behalf of the  
360 Fertility Society of Australia).

361 The scientific evidence supporting this change came largely from a detailed immunohistochemical  
362 study of endometrial biopsies taken at ovum pickup, with final analyses comparing women who  
363 did/did not become pregnant following embryo transfer in that IVF cycle. Critically, most tissues  
364 were highly disturbed by the hormonal treatments compared with samples from unstimulated women.  
365 Only endometrium with a score close to normal controls supported pregnancy (Evans, et al. 2012).  
366 Furthermore, a separate investigation showed that hCG stimulation of ovulation, makes the  
367 endometrium refractory to subsequent embryonic hCG signalling, which promotes receptivity (Evans  
368 and Salamonsen 2013).

#### 369 Lifestyle factors influencing women’s fertility

370 Many lifestyle factors contribute to infertility in both men and women; these include age, nutrition,  
371 weight, exercise and environmental exposures. Reduction in cigarette smoking, illicit drug use,  
372 alcohol and caffeine consumption are all of proven benefit and some of the underpinning molecular  
373 mechanisms are known (Sharma, et al. 2013). Obesity is a known risk factor for ovulation defects,  
374 but growing evidence implicates obesity in mediating endometrial dysfunction (reviewed in  
375 (Antoniotti, et al. 2018). By explanation, a family of post-translational modifications of fat and  
376 sugar-related molecules, known as advanced glycation end products (AGEs), which are elevated  
377 systemically in women with high BMI, are at high concentrations in the uterine cavity of these  
378 women. Importantly AGEs adversely impact both endometrial function and embryo implantation



379 competence (Antoniotti, et al. 2018), Since AGE levels can be lowered by diet (de Courten, et al.  
380 2016) or by pharmaceutical means (Coughlan, et al. 2007), this offers hope to those infertile women  
381 with obesity and/or related metabolic disorders.

382

### 383 Blood test for endometrial receptivity

384 A major need in IVF clinics is for a test to indicate whether fresh embryo transfer is likely to be  
385 successful. Following our extensive analysis of uterine fluid, a cohort of cytokines measured in  
386 uterine fluid taken on the day of ovum pickup, has proven to be a highly effective test for uterine  
387 receptivity in the cycle of sampling: it clearly differentiates between women who will have a  
388 successful transfer in that cycle and those who will not (Edgell, et al. 2018). A modification of this  
389 test is equally effective if applied to serum samples similarly taken at the time of ovum pickup  
390 (Edgell and Salamonsen, unpublished data).

391

392 We anticipate that manipulation of the uterine microenvironment using one or more of the factors  
393 dysregulated in infertile women may be effective in treating endometrial infertility without need for  
394 IVF.

395

### 396 Beyond the endometrium: scar-free wound repair

397 Endometrial repair following menstruation is unique among adult tissues in that it occurs very  
398 rapidly and without scarring. Endometrial destruction occurs at focal points and re-epithelialization  
399 follows immediately to cover the endometrial surface: thus repair occurs in the presence of  
400 menstrual effluent. From the proteomic data discussed above, several menstrual fluid proteins were  
401 functionally active in endometrial repair assays (Evans, et al. 2018). Testing was also successfully  
402 applied to wound repair models, including in vivo wound repair in pigs. Unlike other known wound

403 repair proteins, which promote cellular proliferation, and have a potential hazard of stimulating  
404 cancers, the menstrual fluid proteins enhanced cellular migration and initial re-epithelialization of  
405 wounds. It is predicted that these factors will extend current wound repair paradigms, maybe  
406 reducing the risk of scarring and providing effective treatment of chronic non-healing wounds.

407

#### 408 **Contraceptive targets**

409 One major ambition has remained unfulfilled: to provide a novel non-hormonal contraceptive for  
410 women that need only be utilized in any cycle in which coitus occurs. In the early 1990s we  
411 proposed that maintenance of the endometrium in a non-receptive state throughout the cycle (by  
412 inhibiting the development of receptivity), would provide very effective contraception. Funding  
413 for such development was available in the 1990s -2000s: we proved that blocking the actions of  
414 PC6 and its substrates, or IL11 would be effective. PC6 is a particularly exciting target since it is  
415 also essential for HIV infectivity through the vagina. Subsequently, numerous other potential  
416 targets have been identified. In women, it is difficult to directly target the endometrium or uterine  
417 cavity. The teams of Nie and Dimitriadis, working with inhibitors of PC6 and IL11 respectively,  
418 investigated modes for local administration in mice, particularly vaginal gels which could provide  
419 simultaneous protection from pregnancy and infection (Ho, et al. 2014, Menkhorst, et al. 2011).  
420 The inhibitors used were effective and clearly reached the mouse endometrium via a “first pass  
421 effect’ from the vaginal circulation. Whether this would also be the case in women is not known:  
422 progestins which are of very low molecular weight, can be delivered via the vagina. We now  
423 anticipate that delivery of inhibitors via exosomes/nanoparticles with target specificity to  
424 endometrial epithelium (a current major interest of ours) may provide a solution to local delivery.  
425 A major advantage of targeting the endometrium, is that it is shed in each menstrual cycle and thus  
426 actions of inhibitors in one cycle would not be maintained and hence not be systemically harmful.

427 The major obstacles remaining to achieve such contraception, are twofold. Firstly systems for direct  
428 delivery to the uterine cavity need to be developed, and secondly, the political demands that  
429 contraception for women be targeted only at pre-fertilization events, needs to be overcome. This is  
430 clearly regrettable in a world where non-steroidal contraceptive methods for women remain a global  
431 need and in which a majority of women are not confined by the values of a few (Crosignani and  
432 Glasier 2012). Indeed, promotion of family planning so that women can avoid unwanted pregnancy,  
433 is central to achieving the Millennium Development Goal on improving maternal health, reducing  
434 child mortality and eliminating extreme poverty (Cleland, et al. 2006).

### 435 **Conclusions.**

436 It has been a privilege and a great pleasure to contribute to our knowledge of endometrial function  
437 and women's health. However, this would not have been possible without the many others working  
438 in the field, a number of whom have become collaborators and friends. Together we have built a  
439 strong body of knowledge from which clinical solutions to a number of disorders affecting women  
440 will evolve and which will resolve often 'silent suffering'. My generation's field of endeavour is  
441 now passing to the hands of the wonderful younger scientists we have trained: I have every  
442 confidence that they will deliver the important outcomes needed.

### 443 **Conflicts of interest**

444 No conflicts of interest to report.

### 445 **Acknowledgments**

446 I particularly acknowledge and thank all the students, post-doctoral scientists and senior scientists  
447 who have contributed to the work from my laboratory, as discussed here. Many have now progressed  
448 to independent and highly successful careers. It has been my great pleasure to work with each of  
449 them.

450 **Current funding** for the Salamonsen laboratory is from the NHMRC of Australia (Project grant  
451 #1139489, Development grant # 1159714), and the Victorian Government Operational Infrastructure  
452 Research Support to the Hudson Institute of Medical Research.

453

#### 454 **Figure legends**

455

456 Figure 1. The menstrual cascade is a highly controlled process of inflammation and tissue  
457 degradation. In brief, during the late secretory phase of the cycle and in the absence of a pregnancy,  
458 the falling levels of progesterone and estrogen stimulate production of chemokines and cytokines by  
459 endometrial decidualized stromal cells and epithelial cells. These result in entry of large numbers of  
460 leukocytes into the tissue, which become activated locally and stimulate production of degradative  
461 enzymes, particularly matrix metalloproteinases in their latent forms which also become activated.  
462 These then degrade the extracellular matrix of the tissue, resulting in shedding and concomitant  
463 bleeding. The photomicrographs show: (A) staining of menstrual tissue with CD45, indicating that  
464 40-50% of the cells in the tissue are of leukocyte origin; (B) inactive mast cells in the tissue, become  
465 activated releasing their granular contents (shown here staining for mast cell tryptase); (C) in situ  
466 zymography of day 2 menstrual tissue, indicating active MMP2 and MMP9, at very focal points in  
467 the tissue, thus explaining the piecemeal tissue shedding.

468

469 Figure 2. The early stages of human implantation. The unhatched blastocyst enters the uterine cavity,  
470 where it sheds the zona pellucida, and undergoes further development as it becomes apposed to the  
471 uterine surface. At this time decidualization is initiated close to the blood vessels from which  
472 macrophages and uterine natural killer cells are attracted into and through the endometrium along a  
473 chemokine gradient. The microenvironment within the uterine cavity (including soluble factors and  
474 extracellular vesicles secreted from both the epithelium and trophectoderm) promote phenotypic

475 changes in both apposing cell types, necessary for implantation. Changes in adhesive properties  
476 enable blastocyst attachment to the endometrial epithelial surface, which is undergoing a partial  
477 epithelial to mesenchymal transformation – the reduced polarity enables trophoctodermal cells to  
478 penetrate the epithelial surface, under which they form a syncytium; some cells escape to invade the  
479 blood vessels which they transform. M; macrophage, NK; uterine natural killer cells, bv; blood  
480 vessel.

481

482 Figure 3. The total secretome of the ECC1 cell line (representative of endometrial epithelial cells),  
483 comprises both a soluble proteome and a proteome contained in secreted exosomes. These  
484 proteomes were analysed following incubation of the ECC1 cells under conditions representing the  
485 proliferative (estrogen) and the secretory (estrogen plus progesterone) phases of the menstrual cycle.  
486 The Venn diagrams clearly establish that while there are proteins in common between the two  
487 proteomes, the majority of proteins are specific to either the soluble or exosomal compartments.  
488 There were also many protein differences between the two hormonal treatments (modified from  
489 Greening et al, 2016b).

490 **References**

- 491 **Antoniotti, GS, M Coughlan, LA Salamonsen, and J Evans** 2018 Obesity associated advanced  
 492 glycation end products within the human uterine cavity adversely impact endometrial  
 493 function and embryo implantation competence. *Hum Reprod* **33** 654-665.
- 494 **Aplin, JD, and PT Ruane** 2017 Embryo-epithelium interactions during implantation at a glance. *J*  
 495 *Cell Sci* **130** 15-22.
- 496 **Armstrong, GM, JA Maybin, AA Murray, M Nicol, C Walker, PTK Saunders, AG Rossi, and**  
 497 **HOD Critchley** 2017 Endometrial apoptosis and neutrophil infiltration during menstruation  
 498 exhibits spatial and temporal dynamics that are recapitulated in a mouse model. *Sci Rep* **7**  
 499 17416.
- 500 **Bellofiore, N, S Rana, H Dickinson, P Temple-Smith, and J Evans** 2018 Characterization of  
 501 human-like menstruation in the spiny mouse: comparative studies with the human and  
 502 induced mouse model. *Hum Reprod* **33** 1715-1726.
- 503 **Berson, SA, and RS Yalow** 1968 General principles of radioimmunoassay. *Clin Chim Acta* **22** 51-  
 504 69.
- 505 **Binder, NK, J Evans, DK Gardner, LA Salamonsen, and NJ Hannan** 2014 Endometrial signals  
 506 improve embryo outcome: functional role of vascular endothelial growth factor isoforms on  
 507 embryo development and implantation in mice. *Hum Reprod* **29** 2278-2286.
- 508 **Binder, NK, J Evans, LA Salamonsen, DK Gardner, TJ Kaitu'u-Lino, and NJ Hannan** 2016  
 509 Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important  
 510 Functions during Embryo Development and Implantation. *PLoS One* **11** e0163096.
- 511 **Boomsma, CM, A Kavelaars, MJ Eijkemans, K Amarouchi, G Teklenburg, D Gutknecht, BJ**  
 512 **Fauser, CJ Heijnen, and NS Macklon** 2009 Cytokine profiling in endometrial secretions: a  
 513 non-invasive window on endometrial receptivity. *Reprod Biomed Online* **18** 85-94.
- 514 **Brasted, M, CA White, TG Kennedy, and LA Salamonsen** 2003 Mimicking the Events of  
 515 Menstruation in the Murine Uterus. *Biol Reprod* **69** 1273-1280.
- 516 **Brighton, PJ, Y Maruyama, K Fishwick, P Vrljicak, S Tewary, R Fujihara, J Muter, ES Lucas,**  
 517 **T Yamada, L Woods, et al** 2017 Clearance of senescent decidual cells by uterine natural  
 518 killer cells in cycling human endometrium. *Elife* **6**.
- 519 **Brinsden, PR, V Alam, B de Moustier, and P Engrand** 2009 Recombinant human leukemia  
 520 inhibitory factor does not improve implantation and pregnancy outcomes after assisted  
 521 reproductive techniques in women with recurrent unexplained implantation failure. *Fertil*  
 522 *Steril* **91** 1445-1447.
- 523 **Burton, GJ, AL Watson, J Hempstock, JN Skepper, and E Jauniaux** 2002 Uterine glands  
 524 provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. *J*  
 525 *Clin Endocrinol Metab* **87** 2954-2959.
- 526 **Casado-Vela, J, E Rodriguez-Suarez, I Iloro, A Ametzazurra, N Alkorta, JA Garcia-Velasco, R**  
 527 **Matorras, B Prieto, S Gonzalez, D Nagore, et al.** 2009 Comprehensive proteomic analysis  
 528 of human endometrial fluid aspirate. *J Proteome Res* **8** 4622-4632.
- 529 **Cleland, J, S Bernstein, A Ezeh, A Faundes, A Glasier, and J Innis** 2006 Family planning: the  
 530 unfinished agenda. *Lancet* **368** 1810-1827.
- 531 **Coughlan, MT, V Thallas-Bonke, J Pete, DM Long, A Gasser, DC Tong, M Arnstein, SR**  
 532 **Thorpe, ME Cooper, and JM Forbes** 2007 Combination therapy with the advanced  
 533 glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme  
 534 inhibitors in diabetes: synergy or redundancy? *Endocrinology* **148** 886-895.
- 535 **Cousins, FL, PM Kirkwood, AA Murray, F Collins, DA Gibson, and PT Saunders** 2016  
 536 Androgens regulate scarless repair of the endometrial "wound" in a mouse model of  
 537 menstruation. *FASEB J* **30** 2802-2811.

- 538 **Cousins, FL, A Murray, A Esnal, DA Gibson, HO Critchley, and PT Saunders** 2014 Evidence  
539 from a mouse model that epithelial cell migration and mesenchymal-epithelial transition  
540 contribute to rapid restoration of uterine tissue integrity during menstruation. *PLoS One* **9**  
541 e86378.
- 542 **Crosignani, PG, and A Glasier** 2012 Family planning 2011: better use of existing methods, new  
543 strategies and more informed choices for female contraception. *Hum Reprod Update* **18** 670-  
544 681.
- 545 **de Courten, B, MP de Courten, G Soldatos, SL Dougherty, N Straznicki, M Schlaich, KC**  
546 **Sourris, V Chand, JL Scheijen, BA et al.** 2016 Diet low in advanced glycation end  
547 products increases insulin sensitivity in healthy overweight individuals: a double-blind,  
548 randomized, crossover trial. *Am J Clin Nutr* **103** 1426-1433.
- 549 **Denker, HW** 1993 Implantation: a cell biological paradox. *J Exp Zool* **266** 541-558.
- 550 **Edgell, TA, J Evans, L Lazzaro, K Boyes, M Sridhar, S Catt, LJF Rombauts, BJ Vollenhoven,**  
551 **and LA Salamonsen** 2018 Assessment of potential biomarkers of pre-receptive and  
552 receptive endometrium in uterine fluid and a functional evaluation of the potential role of  
553 CSF3 in fertility. *Cytokine* **111** 222-229.
- 554 **Evans, J, NJ Hannan, TA Edgell, BJ Vollenhoven, PJ Lutjen, T Osianlis, LA Salamonsen, and**  
555 **LJ Rombauts** 2014 Fresh versus frozen embryo transfer: backing clinical decisions with  
556 scientific and clinical evidence. *Hum Reprod Update* **20** 808-821.
- 557 **Evans, J, NJ Hannan, C Hincks, LJ Rombauts, and LA Salamonsen** 2012 Defective soil for a  
558 fertile seed? Altered endometrial development is detrimental to pregnancy success. *PLoS One*  
559 **7** e53098.
- 560 **Evans, J, G Infusini, J McGovern, L Cuttle, A Webb, T Nebl, L Milla, R Kimble, M Kempf, CJ**  
561 **Andrews, et al.** 2018 Menstrual fluid factors facilitate tissue repair: identification and  
562 functional action in endometrial and skin repair. *FASEB J* fj201800086R.
- 563 **Evans, J, T Kaitu'u-Lino, and LA Salamonsen** 2011 Extracellular matrix dynamics in scar-free  
564 endometrial repair: perspectives from mouse in vivo and human in vitro studies. *Biol Reprod*  
565 **85** 511-523.
- 566 **Evans, J, and LA Salamonsen** 2012 Inflammation, leukocytes and menstruation. *Rev Endocr Metab*  
567 *Disord* **13** 277-288.
- 568 **Evans, J, and LA Salamonsen** 2013 Too much of a good thing? Experimental evidence suggests  
569 prolonged exposure to hCG is detrimental to endometrial receptivity. *Hum Reprod* **28** 1610-  
570 1619.
- 571 **Ferenczy, A, and RM Richart** 1973 Scanning and transmission electron microscopy of the human  
572 endometrial surface epithelium. *J Clin Endocrinol Metab* **36** 999-1008.
- 573 **Filant, J, and TE Spencer** 2013 Endometrial glands are essential for blastocyst implantation and  
574 decidualization in the mouse uterus. *Biol Reprod* **88** 93.
- 575 **Finn, CA** 1986 Implantation, menstruation and inflammation. *Biol Rev Camb Philos Soc* **61** 313-328.
- 576 **Finn, CA, and M Pope** 1984 Vascular and cellular changes in the decidualized endometrium of the  
577 ovariectomized mouse following cessation of hormone treatment: a possible model for  
578 menstruation. *J. Endocrinol.* **100** 295-300.
- 579 **Fitzgerald, HC, J Evans, N Johnson, G Infusini, A Webb, LJR Rombauts, BJ Vollenhoven, LA**  
580 **Salamonsen, and TA Edgell** 2018 Idiopathic infertility in women is associated with distinct  
581 changes in proliferative phase uterine fluid proteins. *Biol Reprod* **98** 752-764.
- 582 **Fitzgerald, HC, LA Salamonsen, LJ Rombauts, BJ Vollenhoven, and TA Edgell** 2016 The  
583 proliferative phase underpins endometrial development: Altered cytokine profiles in uterine  
584 lavage fluid of women with idiopathic infertility. *Cytokine* **88** 12-19.
- 585 **Gaide Chevronnay, HP, C Selvais, H Emonard, C Galant, E Marbaix, and P Henriot** 2012  
586 Regulation of matrix metalloproteinases activity studied in human endometrium as a  
587 paradigm of cyclic tissue breakdown and regeneration. *Biochim Biophys Acta* **1824** 146-156.

- 588 **Gray, CA, KM Taylor, WS Ramsey, JR Hill, FW Bazer, FF Bartol, and TE Spencer** 2001  
 589 Endometrial glands are required for preimplantation conceptus elongation and survival. *Biol*  
 590 *Reprod* **64** 1608-1613.
- 591 **Greening, DW, HP Nguyen, K Elgass, RJ Simpson, and LA Salamonsen** 2016a Human  
 592 Endometrial Exosomes Contain Hormone-Specific Cargo Modulating Trophoblast Adhesive  
 593 Capacity: Insights into Endometrial-Embryo Interactions. *Biol Reprod* **94** 38.
- 594 **Greening, DW, HP Nguyen, J Evans, RJ Simpson, and LA Salamonsen** 2016b Modulating the  
 595 endometrial epithelial proteome and secretome in preparation for pregnancy: The role of  
 596 ovarian steroid and pregnancy hormones. *J Proteomics* **144** 99-112.
- 597 **Hampton, AL, and LA Salamonsen** 1994 Expression of messenger ribonucleic acid encoding  
 598 matrix metalloproteinases and their tissue inhibitors is related to menstruation. *J Endocrinol*  
 599 **141** R1-3.
- 600 **Hanna, J, D Goldman-Wohl, Y Hamani, I Avraham, C Greenfield, S Natanson-Yaron, D Prus,**  
 601 **L Cohen-Daniel, TI Arnon, I Manaster et al.** 2006 Decidual NK cells regulate key  
 602 developmental processes at the human fetal-maternal interface. *Nat Med* **12** 1065-1074.
- 603 **Hannan, NJ, G Nie, A Rainczuk, LJ Rombauts, and LA Salamonsen** 2012 Uterine lavage or  
 604 aspirate: which view of the intrauterine environment? *Reprod Sci* **19** 1125-1132.
- 605 **Hannan, NJ, P Paiva, KL Meehan, LJ Rombauts, DK Gardner, and LA Salamonsen** 2011  
 606 Analysis of fertility-related soluble mediators in human uterine fluid identifies VEGF as a  
 607 key regulator of embryo implantation. *Endocrinology* **152** 4948-4956.
- 608 **Hannan, NJ, AN Stephens, A Rainczuk, C Hincks, LJ Rombauts, and LA Salamonsen** 2010  
 609 2D-DiGE analysis of the human endometrial secretome reveals differences between receptive  
 610 and nonreceptive states in fertile and infertile women. *J Proteome Res* **9** 6256-6264.
- 611 **Hannan, NJ, CJ Stoikos, AN Stephens, and LA Salamonsen** 2009 Depletion of high-abundance  
 612 serum proteins from human uterine lavages enhances detection of lower-abundance proteins.  
 613 *J Proteome Res* **8** 1099-1103.
- 614 **Heng, S, A Cervero, C Simon, AN Stephens, Y Li, J Zhang, S Paule, A Rainczuk, H Singh, A**  
 615 **Quinonero, A Tapia et al.** 2011 Proprotein convertase 5/6 is critical for embryo  
 616 implantation in women: regulating receptivity by cleaving EBP50, modulating ezrin binding,  
 617 and membrane-cytoskeletal interactions. *Endocrinology* **152** 5041-5052.
- 618 **Heng, S, SG Paule, Y Li, LJ Rombauts, B Vollenhoven, LA Salamonsen, and G Nie** 2015  
 619 Posttranslational removal of alpha-dystroglycan N terminus by PC5/6 cleavage is important  
 620 for uterine preparation for embryo implantation in women. *FASEB J* **29** 4011-4022.
- 621 **Hickey, M, J Crewe, LA Mahoney, DA Doherty, IS Fraser, and LA Salamonsen** 2006  
 622 Mechanisms of irregular bleeding with hormone therapy: the role of matrix  
 623 metalloproteinases and their tissue inhibitors. *J Clin Endocrinol Metab* **91** 3189-3198.
- 624 **Ho, H, Y Li, and G Nie** 2014 Inhibition of embryo implantation in mice through vaginal  
 625 administration of a proprotein convertase 6 inhibitor. *Reprod Biol* **14** 155-159.
- 626 **Jeziorska, M, H Nagase, LA Salamonsen, and DE Woolley** 1996 Immunolocalization of the  
 627 matrix metalloproteinases gelatinase B and stromelysin 1 in human endometrium throughout  
 628 the menstrual cycle. *J Reprod Fertil* **107** 43-51.
- 629 **Kaitu'u-Lino, TJ, NB Morison, and LA Salamonsen** 2007a Estrogen is not essential for full  
 630 endometrial restoration after breakdown: lessons from a mouse model. *Endocrinology* **148**  
 631 5105-5111.
- 632 **Kaitu'u-Lino, TJ, NB Morison, and LA Salamonsen** 2007b Neutrophil depletion retards  
 633 endometrial repair in a mouse model. *Cell Tissue Res* **328** 197-206.
- 634 **Kaitu'u-Lino, TJ, DJ Phillips, NB Morison, and LA Salamonsen** 2009 A new role for activin in  
 635 endometrial repair after menses. *Endocrinology* **150** 1904-1911.



- 636 **Licht, P, V Russu, S Lehmeyer, and L Wildt** 2001 Molecular aspects of direct LH/hCG effects on  
 637 human endometrium--lessons from intrauterine microdialysis in the human female in vivo.  
 638 *Reprod.Biol.* **1** 10-19.
- 639 **Lopata, A, F Agresta, MA Quinn, C Smith, AG Ostor, and LA Salamonsen** 2003 Detection of  
 640 endometrial cancer by determination of matrix metalloproteinases in the uterine cavity.  
 641 *Gynecol Oncol* **90** 318-324.
- 642 **Ludwig, H, and UM Spornitz** 1991 Microarchitecture of the human endometrium by scanning  
 643 electron microscopy: menstrual desquamation and remodeling. *Ann N Y Acad Sci* **622** 28-46.
- 644 **Luu, KC, GY Nie, A Hampton, G-Q Fu, Y-X Liu, and LA Salamonsen** 2004 Endometrial  
 645 expression of calbindin (CaBP)-d28k but not CaBP-d9k in primates implies evolutionary  
 646 changes and functional redundancy of calbindins at implantation. *Reproduction* **128** 433-441.
- 647 **Lydon, JP, FJ DeMayo, CR Funk, SK Mani, AR Hughes, CA Montgomery, Jr., G Shyamala,  
 648 OM Conneely, and BW O'Malley** 1995 Mice lacking progesterone receptor exhibit  
 649 pleiotropic reproductive abnormalities. *Genes Dev* **9** 2266-2278.
- 650 **Macklon, NS, JP Geraedts, and BC Fauser** 2002 Conception to ongoing pregnancy: the 'black box'  
 651 of early pregnancy loss. *Hum Reprod Update.* **8** 333-343.
- 652 **Marbaix, E, J Donnez, PJ Courtoy, and Y Eeckhout** 1992 Progesterone regulates the activity of  
 653 collagenase and related gelatinases A and B in human endometrial explants. *Proc Natl Acad  
 654 Sci U S A* **89** 11789-11793.
- 655 **Marbaix, E, I Kokorine, P Moulin, J Donnez, Y Eeckhout, and PJ Courtoy** 1996 Menstrual  
 656 breakdown of human endometrium can be mimicked in vitro and is selectively and reversibly  
 657 blocked by inhibitors of matrix metalloproteinases. *Proc Natl Acad Sci U S A* **93** 9120-9125.
- 658 **Martin, JC, MJ Jasper, D Valbuena, M Meseguer, J Remohi, A Pellicer, and C Simon** 2000  
 659 Increased adhesiveness in cultured endometrial-derived cells is related to the absence of  
 660 moesin expression. *Biol Reprod* **63** 1370-1376.
- 661 **Maybin, JA, AA Murray, PTK Saunders, N Hirani, P Carmeliet, and HOD Critchley** 2018  
 662 Hypoxia and hypoxia inducible factor-1alpha are required for normal endometrial repair  
 663 during menstruation. *Nat Commun* **9** 295.
- 664 **Menkhorst, E, LA Salamonsen, J Zhang, CA Harrison, J Gu, and E Dimitriadis** 2010  
 665 Interleukin 11 and activin A synergise to regulate progesterone-induced but not cAMP-  
 666 induced decidualization. *J Reprod Immunol* **84** 124-132.
- 667 **Menkhorst, E, JG Zhang, NA Sims, PO Morgan, P Soo, IJ Poulton, D Metcalf, E Alexandrou,  
 668 M Gresle, LA Salamonsen et al.** 2011 Vaginally administered PEGylated LIF antagonist  
 669 blocked embryo implantation and eliminated non-target effects on bone in mice. *PLoS One* **6**  
 670 e19665.
- 671 **Menning, A, A Walter, M Rudolph, I Gashaw, KH Fritzscheier, and L Roese** 2012 Granulocytes  
 672 and vascularization regulate uterine bleeding and tissue remodeling in a mouse menstruation  
 673 model. *PLoS One* **7** e41800.
- 674 **Murphy, CR** 2004 Uterine receptivity and the plasma membrane transformation. *Cell Res* **14** 259-  
 675 267.
- 676 **Navot, D, PA Bergh, M Williams, GJ Garrisi, I Guzman, B Sandler, J Fox, P Schreiner-Engel,  
 677 GE Hofmann, and L Grunfeld** 1991 An insight into early reproductive processes through  
 678 the in vivo model of ovum donation. *J Clin Endocrinol Metab* **72** 408-414.
- 679 **Ng, YH, S Rome, A Jalabert, A Forterre, H Singh, CL Hincks, and LA Salamonsen** 2013  
 680 Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for  
 681 embryo-endometrial cross talk at implantation. *PLoS One* **8** e58502.
- 682 **Nguyen, HP, RJ Simpson, LA Salamonsen, and DW Greening** 2016 Extracellular Vesicles in the  
 683 Intrauterine Environment: Challenges and Potential Functions. *Biol Reprod* **95** 109.
- 684 **Nie, G-Y, Y Li, AL Hampton, LA Salamonsen, JA Clements, and JK Findlay** 2000a  
 685 Identification of monoclonal nonspecific suppressor factor beta (MNSFbeta) as one of the

- 686 genes differentially expressed at implantation sites compared to interimplantation sites in the  
 687 mouse uterus. *Mol Reprod Dev* **55** 351-363.
- 688 **Nie, G-Y, Y Li, J Wang, H Minoura, JK Findlay, and LA Salamonsen** 2000b Complex  
 689 regulation of calcium-binding protein D9k (Calbindin-D9k) in the mouse uterus during early  
 690 pregnancy and at the site of embryo implantation. *Biol. Reprod.* **62** 27-36.
- 691 **Nie, GY, A Hampton, Y Li, JK Findlay, and LA Salamonsen** 2003a Identification and cloning of  
 692 two isoforms of human HtrA3, characterisation of its genomic structure and comparison of its  
 693 tissue distribution with HtrA1 and HtrA2. *Biochem.J* **371** 39-48.
- 694 **Nie, GY, AL Hampton, GQ Fu, YX Liu, JK Findlay, and LA Salamonsen** 2002 A potential  
 695 molecular mechanism for regulating pre-mRNA splicing of implantation-related genes  
 696 through unique uterine expression of splicing factor SC35 in women and rhesus monkeys.  
 697 *Reprod.* **124** 209-217.
- 698 **Nie, GY, Y Li, H Minoura, JK Findlay, and LA Salamonsen** 2003b Specific and transient up-  
 699 regulation of proprotein convertase 6 at the site of embryo implantation and identification of  
 700 a unique transcript in mouse uterus during early pregnancy. *Biol. Reprod.* **68** 439-447.
- 701 **Paiva, P, NJ Hannan, C Hincks, KL Meehan, E Pruyers, E Dimitriadis, and LA Salamonsen**  
 702 2011 Human chorionic gonadotrophin regulates FGF2 and other cytokines produced by  
 703 human endometrial epithelial cells, providing a mechanism for enhancing endometrial  
 704 receptivity. *Hum Reprod* **26** 1153-1162.
- 705 **Paiva, P, E Menkhorst, L Salamonsen, and E Dimitriadis** 2009 Leukemia inhibitory factor and  
 706 interleukin-11: critical regulators in the establishment of pregnancy. *Cytokine Growth Factor*  
 707 *Rev* **20** 319-328.
- 708 **Paule, S, M Aljofan, C Simon, LJ Rombauts, and G Nie** 2012 Cleavage of endometrial alpha-  
 709 integrins into their functional forms is mediated by proprotein convertase 5/6. *Hum Reprod*  
 710 **27** 2766-2774.
- 711 **Rawdanowicz, TJ, AL Hampton, H Nagase, DE Woolley, and LA Salamonsen** 1994 Matrix  
 712 metalloproteinase production by cultured human endometrial stromal cells: identification of  
 713 interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential  
 714 regulation by interleukin-1 alpha and tumor necrosis factor-alpha. *J Clin Endocrinol Metab*  
 715 **79** 530-536.
- 716 **Rodgers, WH, LM Matrisian, LC Giudice, B Dsupin, P Cannon, C Svitek, F Gorstein, and KG**  
 717 **Osteen** 1994 Patterns of matrix metalloproteinase expression in cycling endometrium imply  
 718 differential functions and regulation by steroid hormones. *J Clin Invest* **94** 946-953.
- 719 **Salamonsen LA, DB, Findlay JK** 1986 The effects of the preimplantation blastocyst in vivo and in  
 720 vitro on protein synthesis and secretion by cultured epithelial cells from sheep endometrium. .  
 721 *Endocrinology* **119** 622-628.
- 722 **Salamonsen, LA, T Edgell, LJ Rombauts, AN Stephens, DM Robertson, A Rainczuk, G Nie,**  
 723 **and NJ Hannan** 2013 Proteomics of the human endometrium and uterine fluid: a pathway to  
 724 biomarker discovery. *Fertil Steril* **99** 1086-1092.
- 725 **Salamonsen, LA, J Evans, HP Nguyen, and TA Edgell** 2016 The Microenvironment of Human  
 726 Implantation: Determinant of Reproductive Success. *Am J Reprod Immunol* **75** 218-225.
- 727 **Salamonsen, LA, HA Jonas, HG Burger, JM Buckmaster, WA Chamley, IA Cumming, JK**  
 728 **Findlay, and JR Goding** 1973 A heterologous radioimmunoassay for follicle stimulating  
 729 hormone: application to measurement of FSH in the ovine estrous cycle, and in several other  
 730 species including man. *Endocrinology* **93** 610-618.
- 731 **Salamonsen, LA, and LJ Lathbury** 2000 Endometrial leukocytes and menstruation. *Hum Reprod*  
 732 *Update* **6** 16-27.
- 733 **Salamonsen, LA, SO Wai, B Doughton, and JK Findlay** 1985 The effects of estrogen and  
 734 progesterone in vivo on protein synthesis and secretion by cultured epithelial cells from sheep  
 735 endometrium. *Endocrinology* **117** 2148-2159.

- 736 **Salamonsen, LA, and DE Woolley** 1999 Menstruation: induction by matrix metalloproteinases and  
737 inflammatory cells. *J Reprod Immunol* **44** 1-27.
- 738 **Salamonsen, LAEJ** 2018 Menstruation and Endometrial Repair. In M.K.Skinner (ed.),  
739 Encyclopedia of Reproduction,, pp. 320-325. Elsevier Inc, Academic Press.
- 740 **Scotchie, JG, MA Fritz, M Mocanu, BA Lessey, and SL Young** 2009 Proteomic analysis of the  
741 luteal endometrial secretome. *Reprod Sci* **16** 883-893.
- 742 **Sharma, R, KR Biedenharn, JM Fedor, and A Agarwal** 2013 Lifestyle factors and reproductive  
743 health: taking control of your fertility. *Reprod Biol Endocrinol* **11** 66.
- 744 **Stewart, CL, P Kaspar, LJ Brunet, H Bhatt, I Gadi, F Kontgen, and SJ Abbondanzo** 1992  
745 Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor.  
746 *Nature* **359** 76-79.
- 747 **Vincent, AJ, N Malakooti, J Zhang, PA Rogers, B Affandi, and LA Salamonsen** 1999  
748 Endometrial breakdown in women using Norplant is associated with migratory cells  
749 expressing matrix metalloproteinase-9 (gelatinase B). *Hum Reprod* **14** 807-815.
- 750 **Vincent, AJ, J Zhang, A Ostor, PA Rogers, B Affandi, G Kovacs, and LA Salamonsen** 2000  
751 Matrix metalloproteinase-1 and -3 and mast cells are present in the endometrium of women  
752 using progestin-only contraceptives. *Hum Reprod* **15** 123-130.
- 753 **Weisberg, E, M Hickey, D Palmer, V O'Connor, LA Salamonsen, JK Findlay, and IS Fraser**  
754 2006 A pilot study to assess the effect of three short-term treatments on frequent and/or  
755 prolonged bleeding compared to placebo in women using Implanon. *Hum Reprod* **21** 295-302.
- 756 **Weisberg, E, M Hickey, D Palmer, V O'Connor, LA Salamonsen, JK Findlay, and IS Fraser**  
757 2009 A randomized controlled trial of treatment options for troublesome uterine bleeding in  
758 Implanon users. *Hum Reprod* **24** 1852-1861.
- 759 **Whitby, S, LA Salamonsen, and J Evans** 2018 The Endometrial Polarity Paradox: Differential  
760 Regulation of Polarity Within Secretory-Phase Human Endometrium. *Endocrinology* **159**  
761 506-518.
- 762 **Wilcox, AJ, DD Baird, and CR Weinberg** 1999 Time of implantation of the conceptus and loss of  
763 pregnancy. *N.Engl.J Med.* **340** 1796-1799.
- 764 **Xiong, S, AM Sharkey, PR Kennedy, L Gardner, LE Farrell, O Chazara, J Bauer, SE Hiby, F**  
765 **Colucci, and A Moffett** 2013 Maternal uterine NK cell-activating receptor KIR2DS1  
766 enhances placentation. *J Clin Invest* **123** 4264-4272.
- 767 **Xu, X, X Chen, Y Li, H Cao, C Shi, S Guan, S Zhang, B He, and J Wang** 2013 Cyclooxygenase-  
768 2 regulated by the nuclear factor-kappaB pathway plays an important role in endometrial  
769 breakdown in a female mouse menstrual-like model. *Endocrinology* **154** 2900-2911.
- 770 **Yap, J, CF Foo, MY Lee, PG Stanton, and E Dimitriadis** 2011 Proteomic analysis identifies  
771 interleukin 11 regulated plasma membrane proteins in human endometrial epithelial cells in  
772 vitro. *Reprod Biol Endocrinol* **9** 73.
- 773 **Zhang, J, AL Hampton, G Nie, and LA Salamonsen** 2000 Progesterone inhibits activation of  
774 latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately  
775 expressed in human endometrium. *Biol Reprod* **62** 85-94.
- 776 **Zhang, J, G Nie, W Jian, DE Woolley, and LA Salamonsen** 1998 Mast cell regulation of human  
777 endometrial matrix metalloproteinases: A mechanism underlying menstruation. *Biol Reprod*  
778 **59** 693-703.
- 779 **Zhang, J, and LA Salamonsen** 2002 In vivo evidence for active matrix metalloproteinases in  
780 human endometrium supports their role in tissue breakdown at menstruation. *J Clin*  
781 *Endocrinol Metab* **87** 2346-2351.

782

## Box 1: Professor Lois A. Salamonsen



Lois has spent her professional life following her passion: understanding the cellular and molecular events that underpin the extraordinary cyclical remodelling of the human endometrium.

She obtained her BSc(hons) in biochemistry at Otago University in New Zealand, where she met her lifelong partner Bob Salamonsen. He and the two sons that followed their marriage have provided continuous support and encouragement to her career. The first ten years focussed on his career development in medicine, which led them to Melbourne, Bergen and Manchester (UK) – in all of these she worked as a research assistant in various laboratories which provided her with a wealth of laboratory skills. On return to Melbourne where they made their home, and with the boys now at school, she obtained a PhD from Monash University and subsequently developed her own laboratory at Prince Henry's Institute.

Lois's career was funded through the Fellowship scheme of NHMRC of Australia where she finally became Senior Principal Research Fellow (NHMRC, 2006-2016). When the Hudson Institute for Medical Research was created through merger of two Institutes, she was appointed Head of the Centre for Reproductive Health. She is also adjunct Professor in the Department of Obstetrics and Gynaecology at Monash University. While now partly retired she still heads the Endometrial Remodelling laboratory at the Hudson Institute.

Her honours include election as a Fellow of: The Australian Academy of Sciences (FAA); the Royal Australasian College of Obstetrics and Gynaecology; the Society for the Study of Reproduction

(USA); and the Society for Reproductive Biology (SRB, Australasia). She is recipient of the Beacon award from Frontiers in Reproduction, and the Founder's lecture of the SRB.

Her team, through >260 publications, are recognized for their contributions to our understanding of endometrial remodelling, the mechanisms underlying menstruation and abnormal uterine bleeding, uterine receptivity, embryo implantation, along with new approaches to female contraception as detailed in the accompanying article. Their focus is on the human, with strong emphasis on translational research.

Current research focuses on the microenvironment of implantation. Identification of the proteins and exosomes in uterine fluid, their regulation and functions both on the endometrium and on the developing embryo and trophectoderm, is providing insights into the complexity of implantation and how it is disturbed in infertile women. The demonstration of strongly detrimental effects of the ovulation induction regimes used in IVF clinics on endometrial receptivity and the potential for implantation, combined with new tests to predict receptivity, should lead to changes in clinical practice and improved IVF outcomes.

Lois has a passion for training young scientists, with a number of her trainees subsequently developing highly productive careers. Some now hold professorial appointments worldwide. Equally, she guides others to appropriate and fulfilling careers outside of research: the adage being that a PhD provides important skills beyond just the research, that can be applied broadly, and that a scientifically informed population is important to society as a whole. Lois is particularly known for her mentorship of young women, who face difficult decisions in combining motherhood and childcare with a high-pressure career in scientific research. She comes to this from her own life experience, that even starting a PhD at 40 is not prohibitive of a productive life in science.

This life has been a privilege and a joy – who could ask for more.

## Some important articles

- Dimitriadis, E, CA White, RL Jones, and LA Salamonsen** 2005 Cytokines, chemokines and growth factors in endometrium related to implantation. *Hum Reprod Update* **11** 613-630.
- Evans, J, NJ Hannan, TA Edgell, BJ Vollenhoven, PJ Lutjen, T Osianlis, LA Salamonsen, and LJ Rombauts** 2014 Fresh versus frozen embryo transfer: backing clinical decisions with scientific and clinical evidence. *Hum Reprod Update* **20** 808-821.
- Evans, J, NJ Hannan, C Hincks, LJ Rombauts, and LA Salamonsen** 2012 Defective soil for a fertile seed? Altered endometrial development is detrimental to pregnancy success. *PLoS One* **7** e53098.
- Evans, J, LA Salamonsen, A Winship, E Menkhorst, G Nie, CE Gargett, and E Dimitriadis** 2016 Fertile ground: human endometrial programming and lessons in health and disease. *Nat Rev Endocrinol* **12** 654-667.
- Greening, DW, HP Nguyen, K Elgass, RJ Simpson, and LA Salamonsen** 2016 Human endometrial exosomes contain hormone-specific cargo modulating trophoblast adhesive capacity: Insights into endometrial-embryo interactions. *Biol Reprod* **94** 38.
- Hannan, NJ, P Paiva, KL Meehan, LJ Rombauts, DK Gardner, and LA Salamonsen** 2011 Analysis of fertility-related soluble mediators in human uterine fluid identifies VEGF as a key regulator of embryo implantation. *Endocrinology* **152** 4948-4956.
- Jones, RL, NJ Hannan, TJ Kaitu'u, J Zhang, and LA Salamonsen** 2004 Identification of chemokines important for leukocyte recruitment to the human endometrium at the times of embryo implantation and menstruation. *J Clin Endocrinol Metab* **89** 6155-6167.
- Ng, YH, S Rome, A Jalabert, A Forterre, H Singh, CL Hincks, and LA Salamonsen** 2013 Endometrial exosomes/microvesicles in the uterine microenvironment: a new paradigm for embryo-endometrial cross talk at implantation. *PLoS One* **8** e58502.

**Rawdanowicz, TJ, AL Hampton, H Nagase, DE Woolley, and LA Salamonsen** 1994 Matrix metalloproteinase production by cultured human endometrial stromal cells: identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha. *J Clin Endocrinol Metab* **79** 530-536.

**Salamonsen, LA, J Evans, HP Nguyen, and TA Edgell** 2016 The microenvironment of human implantation: Determinant of reproductive success. *Am J Reprod Immunol* **75** 218-225.

**Salamonsen, LA, and G Nie** 2002 Proteases at the endometrial-trophoblast interface: their role in implantation. *Rev Endocr Metab Disord* **3** 133-143.

Figure 1




Figure 1. The menstrual cascade is a highly controlled process of inflammation and tissue degradation. In brief, during the late secretory phase of the cycle and in the absence of a pregnancy, the falling levels of progesterone and estrogen stimulate production of chemokines and cytokines by endometrial decidualized stromal cells and epithelial cells. These result in entry of large numbers of leukocytes into the tissue, which become activated locally and stimulate production of degradative enzymes, particularly matrix metalloproteinases in their latent forms which also become activated. These then degrade the extracellular matrix of the tissue, resulting in shedding and concomitant bleeding. The photomicrographs show: (A) staining of menstrual tissue with CD45, indicating that 40-50% of the cells in the tissue are of leukocyte origin; (B) inactive mast cells in the tissue, become activated releasing their granular contents (shown here staining for mast cell tryptase); (C) in situ zymography of day 2 menstrual tissue, indicating active MMP2 and MMP9, at very focal points in the tissue, thus explaining the piecemeal tissue shedding.

254x190mm (96 x 96 DPI)



Figure 2




Figure 2. The early stages of human implantation. The unhatched blastocyst enters the uterine cavity, where it sheds the zona pellucida, and undergoes further development as it becomes apposed to the uterine surface. At this time decidualization is initiated close to the blood vessels from which macrophages and uterine natural killer cells are attracted into and through the endometrium along a chemokine gradient. The microenvironment within the uterine cavity (including soluble factors and extracellular vesicles secreted from both the epithelium and trophoblast) promote phenotypic changes in both apposing cell types, necessary for implantation. Changes in adhesive properties enable blastocyst attachment to the endometrial epithelial surface, which is undergoing a partial epithelial to mesenchymal transformation – the reduced polarity enables trophoblastic cells to penetrate the epithelial surface, under which they form a syncytium; some cells escape to invade the blood vessels which they transform. M; macrophage, NK; uterine natural killer cells, bv; blood vessel.

254x190mm (96 x 96 DPI)

Figure 3




Figure 3. The total secretome of the ECC1 cell line (representative of endometrial epithelial cells), comprises both a soluble proteome and a proteome contained in secreted exosomes. These proteomes were analysed following incubation of the ECC1 cells under conditions representing the proliferative (estrogen) and the secretory (estrogen plus progesterone) phases of the menstrual cycle. The Venn diagrams clearly establish that while there are proteins in common between the two proteomes, the majority of proteins are specific to either the soluble or exosomal compartments. There were also many protein differences between the two hormonal treatments (modified from Greening et al, 2016b).

254x190mm (96 x 96 DPI)